비침습적 산전 검사 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 검사 방법별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Non-invasive Prenatal Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Test Type, By Method, By Application, By End User, By Region and Competition, 2020-2030F
상품코드:1719121
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 183 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
비침습적 산전 검사(NIPT) 세계 시장은 2024년 50억 3,000만 달러로 평가되며, 2030년에는 77억 4,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 7.42%의 CAGR로 성장할 것으로 예상됩니다.
이러한 성장의 원동력은 유전성 질환에 대한 인식의 증가와 보다 안전하고 비침습적인 산전 선별검사의 대안에 대한 수요에 기인합니다. 전 세계적으로 산모의 연령이 계속 증가함에 따라 염색체 이상 위험도 증가하고 있으며, 이에 따라 NIPT가 선호되는 선별검사 옵션으로 채택되고 있습니다. 이 기술은 산모의 간단한 혈액 샘플을 통해 정확한 결과를 제공하며, 양수 천자와 같은 침습적 시술과 관련된 위험을 제거합니다. 조기 진단 이니셔티브에 대한 정부의 지원, 민간 의료 서비스 접근성의 발전, 빠른 결과의 편의성이 시장을 더욱 강화시키고 있습니다. 또한, AI 기반 분석 및 다중 분석법 개발과 같은 기술 혁신은 NIPT의 범위와 정확성을 확대하는 한편, 재택 검사 솔루션에 대한 소비자 수요는 보다 환자 중심의 의료 서비스 제공 모델을 재구성하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
50억 3,000만 달러
시장 규모 : 2030년
77억 4,000만 달러
CAGR : 2025-2030년
7.42%
급성장 부문
삼염색체
최대 시장
북미
시장 촉진요인
모체 연령의 증가와 그에 따른 염색체 이상 위험도 증가
주요 시장 과제
NIPT의 한계
주요 시장 동향
소비자 직접 검사 가능 여부
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 비침습적 산전 검사(NIPT) 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
제품 유형별(소모품, 기기)
검사 종별(Materni 21, Harmony, Panaroma, Verifi, NIFTY, 기타)
방법별(초음파 검사, 생화학 스크리닝 검사, 세포 유리 DNA 산모 혈장 검사, 산모 혈액중 태아 세포 검사, 기타)
용도별(삼염색체, 미세결실 증후군, 기타)
최종사용자별(진단 연구소, 병원, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의 비침습적 산전 검사(NIPT) 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 비침습적 산전 검사(NIPT) 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 비침습적 산전 검사(NIPT) 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 비침습적 산전 검사(NIPT) 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 비침습적 산전 검사(NIPT) 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
인수합병
제품 출시
제13장 세계의 비침습적 산전 검사(NIPT) 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
YOURGENE HEALTH Plc
Illumina, Inc.
Natera, Inc.
F.Hoffman La Roche Ltd.
Perkin Elmer Inc.
Laboratory Corporation of America Holdings
Eurofins LifeCodex GmbH
Progenity, Inc.
Genesis Genetics
Quest Diagnostics Incorporated
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
The Global Non-invasive Prenatal Testing (NIPT) Market was valued at USD 5.03 billion in 2024 and is projected to reach USD 7.74 billion by 2030, growing at a CAGR of 7.42% during the forecast period. This growth is driven by increased awareness of genetic disorders and the demand for safer, non-invasive prenatal screening alternatives. As maternal age continues to rise globally, so does the risk of chromosomal abnormalities, prompting wider adoption of NIPT as a preferred screening option. The technology offers accurate results using a simple blood sample from the mother, eliminating risks associated with invasive procedures like amniocentesis. Government support for early diagnostic initiatives, advancements in private healthcare access, and the convenience of rapid results further bolster the market. Additionally, innovations such as AI-based analysis and multiplex assay development are broadening the scope and precision of NIPT, while consumer demand for home-based testing solutions is reshaping delivery models to become more patient-centric.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 5.03 Billion
Market Size 2030
USD 7.74 Billion
CAGR 2025-2030
7.42%
Fastest Growing Segment
Trisomy
Largest Market
North America
Key Market Drivers
Rising Maternal Age and Associated Risk of Chromosomal Abnormalities
The trend of delayed motherhood, particularly across Europe, is fueling demand for NIPT. As women increasingly postpone childbirth for career or financial reasons, the average maternal age continues to climb-reaching 30.9 years in England and Wales in 2023, according to the ONS. This age shift is associated with heightened risk for chromosomal anomalies like Down syndrome, Edwards syndrome, and Patau syndrome. NIPT has become the preferred screening method due to its high accuracy, non-invasive nature, and safety for both mother and fetus. The growing maternal population over the age of 35 is particularly inclined to choose NIPT over invasive diagnostic tests. The incorporation of NIPT into public healthcare systems such as the NHS has further increased access, supporting its widespread adoption as part of routine prenatal care.
Key Market Challenges
Limitations of NIPT
Despite its advantages, NIPT faces certain limitations that hinder universal adoption. The possibility of false-positive or false-negative results may lead to unnecessary follow-up procedures or missed diagnoses, undermining patient confidence. Since NIPT is a screening-not diagnostic-tool, positive results must be confirmed through invasive testing methods like amniocentesis or CVS, which may deter some from pursuing initial screening. Additionally, NIPT is largely focused on detecting chromosomal abnormalities and may not identify rare or functional genetic disorders, leaving gaps in comprehensive fetal health assessment. Cost also remains a concern, particularly for patients without insurance coverage or in regions where testing is not publicly funded. The lower sensitivity of NIPT for rare conditions and de novo mutations presents further challenges for families seeking exhaustive genetic insights.
Key Market Trends
Availability of Direct-to-Consumer Tests
The emergence of direct-to-consumer (DTC) NIPT is reshaping the market by expanding accessibility and convenience. These at-home testing options enable individuals to initiate genetic screening without visiting a healthcare provider, promoting early decision-making and broader adoption. DTC models align with the broader movement toward personalized and proactive healthcare, offering users greater control over prenatal care choices. They are especially beneficial for individuals in remote or underserved regions who face barriers to in-clinic services. While concerns over result interpretation and medical oversight remain, the convenience and consumer empowerment offered by DTC NIPT options are expected to drive future demand and innovation within the market.
Key Market Players
YOURGENE HEALTH Plc
Illumina, Inc.
Natera, Inc.
F. Hoffman-La Roche Ltd.
PerkinElmer Inc.
Laboratory Corporation of America Holdings
Eurofins LifeCodexx GmbH
Progenity, Inc.
Genesis Genetics
Quest Diagnostics Incorporated
Report Scope:
In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Non-invasive Prenatal Testing (NIPT) Market, By Product Type:
Consumables
Instruments
Non-invasive Prenatal Testing (NIPT) Market, By Test Type:
Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others
Non-invasive Prenatal Testing (NIPT) Market, By Method:
Ultrasound Detection
Biochemical Screening Testing
Cell-Free DNA Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
Others
Non-invasive Prenatal Testing (NIPT) Market, By Application:
Trisomy
Microdeletion Syndrome
Others
Non-invasive Prenatal Testing (NIPT) Market, By End User:
Diagnostic Laboratories
Hospitals
Others
Non-invasive Prenatal Testing (NIPT) Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.
Available Customizations:
Global Non-invasive Prenatal Testing (NIPT) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Consumables, Instruments)
5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Test Type
6.2.3. By Method
6.2.4. By Application
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Test Type
6.3.1.2.3. By Method
6.3.1.2.4. By Application
6.3.1.2.5. By End User
6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Test Type
6.3.2.2.3. By Method
6.3.2.2.4. By Application
6.3.2.2.5. By End User
6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Test Type
6.3.3.2.3. By Method
6.3.3.2.4. By Application
6.3.3.2.5. By End User
7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Test Type
7.2.3. By Method
7.2.4. By Application
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Test Type
7.3.1.2.3. By Method
7.3.1.2.4. By Application
7.3.1.2.5. By End User
7.3.2. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Test Type
7.3.2.2.3. By Method
7.3.2.2.4. By Application
7.3.2.2.5. By End User
7.3.3. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Product Type
7.3.3.2.2. By Test Type
7.3.3.2.3. By Method
7.3.3.2.4. By Application
7.3.3.2.5. By End User
7.3.4. France Non-invasive Prenatal Testing (NIPT) Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Test Type
7.3.4.2.3. By Method
7.3.4.2.4. By Application
7.3.4.2.5. By End User
7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Test Type
7.3.5.2.3. By Method
7.3.5.2.4. By Application
7.3.5.2.5. By End User
8. Asia-Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Test Type
8.2.3. By Method
8.2.4. By Application
8.2.5. By End User
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Test Type
8.3.1.2.3. By Method
8.3.1.2.4. By Application
8.3.1.2.5. By End User
8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Test Type
8.3.2.2.3. By Method
8.3.2.2.4. By Application
8.3.2.2.5. By End User
8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Test Type
8.3.3.2.3. By Method
8.3.3.2.4. By Application
8.3.3.2.5. By End User
8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Test Type
8.3.4.2.3. By Method
8.3.4.2.4. By Application
8.3.4.2.5. By End User
8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Test Type
8.3.5.2.3. By Method
8.3.5.2.4. By Application
8.3.5.2.5. By End User
9. South America Non-invasive Prenatal Testing (NIPT) Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Test Type
9.2.3. By Method
9.2.4. By Application
9.2.5. By End User
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Test Type
9.3.1.2.3. By Method
9.3.1.2.4. By Application
9.3.1.2.5. By End User
9.3.2. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Test Type
9.3.2.2.3. By Method
9.3.2.2.4. By Application
9.3.2.2.5. By End User
9.3.3. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Test Type
9.3.3.2.3. By Method
9.3.3.2.4. By Application
9.3.3.2.5. By End User
10. Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Test Type
10.2.3. By Method
10.2.4. By Application
10.2.5. By End User
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Test Type
10.3.1.2.3. By Method
10.3.1.2.4. By Application
10.3.1.2.5. By End User
10.3.2. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Test Type
10.3.2.2.3. By Method
10.3.2.2.4. By Application
10.3.2.2.5. By End User
10.3.3. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Test Type
10.3.3.2.3. By Method
10.3.3.2.4. By Application
10.3.3.2.5. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Non-invasive Prenatal Testing (NIPT) Market: SWOT Analysis
